Edwards Lifesciences Corporation
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 5.23B | 5.38B | 5.01B | 5.44B | 6.07B | 11.5% | |
| Cost of Revenue | (1.23B) | (1.17B) | (1.04B) | (1.12B) | (1.33B) | 18.7% | |
Gross Profit | 4.01B | 4.22B | 3.97B | 4.32B | 4.74B | 9.7% | |
| Operating Expenses | |||||||
| Research & Development | (903.10M) | (945.20M) | (962.90M) | (1.05B) | (1.08B) | 2.5% | |
| Selling, General & Administrative | (1.49B) | (1.57B) | (1.58B) | (1.79B) | (2.09B) | 16.5% | |
| Depreciation & Amortization | (163.30M) | (166.80M) | (144.90M) | (155.20M) | (156.60M) | 0.9% | |
Operating Income (EBIT) | 1.61B | 1.70B | 1.43B | 1.38B | 1.64B | 18.7% | |
| Non-Operating Items | |||||||
| Interest Income | 17.40M | 35.50M | 67.20M | 120.30M | 148.40M | 23.4% | |
| Interest Expense | (24.80M) | (26.20M) | (17.60M) | (19.80M) | — | -100.0% | |
| Other Income/Expenses (Net) | 91.60M | 65.00M | -54.90M | 169.40M | -363.30M | -314.5% | |
Income Before Tax | 1.70B | 1.77B | 1.37B | 1.55B | 1.27B | -17.8% | |
| Income Tax Expense | (198.90M) | (245.50M) | (152.40M) | (152.10M) | (216.90M) | 42.6% | |
Net Income | 1.50B | 1.52B | 1.40B | 4.17B | 1.07B | -74.3% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $2 | $2 | $2 | $7 | $2 | -73.6% | |
| Weighted Avg Shares Outstanding | 623.30M | 619.00M | 606.70M | 597.70M | 584.80M | -2.2% | |
| Weighted Avg Shares Outstanding (Diluted) | 631.20M | 624.20M | 609.40M | 599.30M | 585.80M | -2.3% | |
EBITDA | 1.89B | 1.96B | 1.53B | 1.72B | 1.43B | -17.0% |
Explore EW
EW in the Healthcare
Large Cap